Biosketch

Mark Monane, MD, MBA

Mark Monane is Chief Medical Officer at Monane Group Clinical Consulting LLC since September 2018. 


Most recently, he joined CardioDx in 2011 and served as Chief Medical Officer from 2011-2018. At CardioDx, he led Clinical/Medical Affairs and serves as Clinical Consultant for the CLIA Laboratory. In this role, Mark focused on molecular diagnostics, clinical utility and economic utility, and payor support. He also directed the publications/presentations strategy and field-based regional medical director programs. Dr. Monane also serves as the Clinical Consultant for the CardioDx CLIA lab. 


Prior to joining CardioDx, he served 11 years as managing director of equity research for Needham & Company, where he focused on emerging biotechnology companies in cancer and cardiovascular disease areas. In this role, he wrote more than 2,500 research summaries including company pipeline reviews, industry overviews, and financial models with a focus on small-mid cap biotechnology stocks in cardiovascular and oncological therapeutics as well as supervised a team of five analysts and associates. Prior to Needham & Company, Mark served as Senior Director of Medical Policy and Practices at Medco Health, where he helped direct pharmaceutical benefit manager strategies and programs for the elderly. Before joining Medco, Dr. Monane was an Assistant Professor at Harvard Medical School and the Harvard School of Public Health, where he completed fellowship training in geriatrics, clinical pharmacology, and clinical effectiveness and centered his research work on optimizing medication use in the elderly around cardiovascular disease and other chronic disorders. His clinical work centered on the care of geriatric patients in the inpatient and outpatient settings at Beth Israel Hospital and Brigham and Women’s Hospital. Mark has more than 50 publications in peer-reviewed and professional journals, focusing on pharmacoepidemiology, pharmacoeconomics, and improving physician prescribing patterns as well as clinical validity, clinical utility, and economic utility of diagnostic tests. 


Mark holds an A.B. and an M.B.A. from Columbia University, an M.S. degree in health policy and management from Harvard University, and an M.D. from New York University. He is board certified in Internal Medicine and is a Fellow of the American College of Physicians, Fellow of the American Heart Association, American Geriatrics Society Fellow, and Fellow of the American Board of Medical Quality. He serves as Adjunct Associate Professor at the Ernest Mario School of Pharmacy at Rutgers University.